Magellan Rx Management Releases New Product Approvals Resource

The months of March, April, and May were eventful for the world of specialty.  This table shows notable specialty product approvals during this period and  their predicted market impact by 2022.  The new approvals covered a wide range of disease categories, including orphan conditions, human immunodeficiency virus (HIV), oncology, inflammatory conditions, and migraine.

These new market entries offer additional treatment options for patients and providers, and furthermore, present both challenges and opportunities to managed care organizations.  Orphan drugs, for example, are often associated with significant high cost as well as limited market competition.  Conversely, additional products in more established categories, such as HIV and inflammatory conditions, may foster increased competition and opportunities for formulary management.